Centessa Pharmaceuticals (CNTA) Financials

$40.50

$0.00 (0.00%)

As on 29-Jun-2026 09:30EDT

Market cap

$6,267 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

12.9

Div. Yield

93.8 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	15.00	--	6.85	--	--
Cost of Revenue	0.47	--	0.94	0.81	0.13	0.03
Gross Profit	-0.47	15.00	-0.94	6.85	-0.13	-0.03
Operating Expenses	256.69	222.69	201.06	178.14	212.26	374.87
Operating Profit (EBIT)	-256.69	-207.69	-201.06	-171.28	-212.26	-374.87
Other Income	--	--	--	--	--	--
Profit before Tax	-249.37	-195.71	-232.91	-176.14	-216.95	-381.79
Provision for Tax	1.27	1.82	2.84	-25.06	-0.75	0.11
Profit after Tax (Net Income)	-250.64	-197.53	-235.76	-151.09	-216.21	-381.90
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-216.21	-381.07

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	487.35	526.86	401.55	236.24	336.17	491.55
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	117.84	117.70	117.26	84.62	69.80	113.44
Current Liabilities	36.57	42.94	58.00	39.39	38.34	24.64
Total Liabilities	678.34	687.50	576.80	360.25	444.31	629.64

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	293.08	319.62	40.39	45.15	6.56	0.86
Current Assets	348.68	367.88	536.41	315.09	437.75	628.77
Total Assets	678.34	687.50	576.80	360.25	444.31	629.64
Total Debt*	7.37	7.57	117.23	84.59	69.80	75.70
Net Current Assets	312.11	324.94	478.41	275.71	399.41	604.14

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-193.82	-142.06	-160.34	-200.55	-136.14
Cash Flow from Investing Activities	--	-418.53	31.27	-127.00	-0.93	63.25
Cash from Financing Activities	--	291.53	364.75	21.12	0.46	660.07
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-1.79	-1.46	-1.79	-1.54	-2.29	-4.25
Cash EPS ($)	--	-1.45	-1.78	-1.54	-2.28	-4.25
Adjusted Book Value ($)	--	3.88	3.04	2.41	3.55	5.47
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-1.43	-1.08	-1.64	-2.12	-1.51
Free Cash Flow per Share ($)	--	-1.43	-1.08	-1.64	-2.13	-1.52

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-37.51	-56.16	-41.58	-44.43	-132.61
ROE (%)	-63.54	-42.55	-73.93	-52.79	-52.24	-154.41
ROA (%)	-40.74	-31.25	-50.32	-37.56	-40.26	-119.09
EBIT Margin (%)	--	-1,228.36	--	-2,425.73	--	--
Net Margin (%)	--	-1,316.88	--	-2,204.65	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	-1.00	--	--	--
EBIT Growth (%)	-24.73	17.31	-34.04	20.72	-50.49	-1,234.59
Net Profit Growth (%)	-11.97	16.21	-56.04	30.12	43.39	-3,481.54
EPS Growth (%)	0.92	0.18	-0.16	0.32	0.46	-41.40
Book Value Growth (%)	9.32	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-17.18	-9.38	-5.16	-1.36	-2.65
Price / Book Value	12.86	6.44	5.51	3.30	0.87	2.06
Dividend Yield (%)	93.83	--	--	--	--	--
EV/EBITDA	1.12	-16.95	-8.32	-3.67	0.15	-3.54
Close Price ($)	39.72	25.01	16.75	7.96	3.10	11.26
High Price ($)	40.25	30.58	18.97	8.65	11.94	26.90
Low Price ($)	9.60	9.60	6.65	3.00	2.89	10.31
Market Cap ($ Cr)	6,266.62	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	0.23	0.01	0.29	0.36	0.21	0.15
Short term debt to equity ratio	--	--	--	--	--	--
Current Ratio	9.53	8.57	9.25	8.00	11.42	25.52
Quick Ratio	9.53	--	--	8.00	12.20	26.24
Interest Coverage	-21.05	-16.08	-22.08	-16.78	-28.81	-54.67

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	402.27	--	571.25	--	--
Asset Turnover	--	0.02	--	0.02	--	--
Receivable days	--	1,286.13	--	1,755.39	--	--
Inventory Days	--	--	0.00	-6,736.43	-66,679.84	-90,283.74
Payable days	--	--	3,673.83	5,761.02	30,550.72	48,870.12
Cash Conversion Cycle	--	--	--	-10,742.06	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.